Abstract
Treatment for patients with advanced ovarian cancer includes a combination of platinum-based chemotherapy and maximally cytoreductive surgery. The 2 options for initial treatment include upfront surgery followed by adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval surgery. Deciding between which approach is a on the basis of several factors: (1) resectability of disease; (2) patient factors such as age, albumin, and body mass index; (3) patient wishes; and (4) overall functional status. Research is needed to further refine these approaches and create a patient-focused treatment plan which includes novel factors such as molecular subtype of disease and frailty and sarcopenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 74-79 |
| Number of pages | 6 |
| Journal | Clinical Obstetrics and Gynecology |
| Volume | 63 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1 2020 |
Keywords
- cytoreduction
- frailty
- ovarian cancer
- residual disease
- surgery
- surgical risk prediction
ASJC Scopus subject areas
- Obstetrics and Gynecology